Unknown

Dataset Information

0

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.


ABSTRACT: Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective ?4?7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much-awaited out-of-class alternatives for patients who have failed or who are intolerant to anti-Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from randomized controlled trials and postmarketing cohort studies and discuss their safety, efficacy, and limitations, in relation to anti-TNF therapy, in optimizing the treatment outcomes.

SUBMITTER: Shim HH 

PROVIDER: S-EPMC6207060 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.

Shim Hang Hock HH   Chan Pak Wo PW   Chuah Sai Wei SW   Schwender Brian J BJ   Kong San Choon SC   Ling Khoon Lin KL  

JGH open : an open access journal of gastroenterology and hepatology 20180620 5


Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much-awaited out-of-class alternatives for patients who have failed or who are intolerant to anti-Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from  ...[more]

Similar Datasets

| S-EPMC8002563 | biostudies-literature
| S-EPMC6090141 | biostudies-literature
| S-EPMC9540102 | biostudies-literature
| S-EPMC6594363 | biostudies-literature
| S-EPMC7055512 | biostudies-literature
| S-EPMC8268556 | biostudies-literature
| S-EPMC4780165 | biostudies-other
| S-EPMC7083298 | biostudies-literature
| S-EPMC7580131 | biostudies-literature
| S-EPMC7408734 | biostudies-literature